Published in Acta Oncol on January 01, 2007
Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. Int J Radiat Oncol Biol Phys (2008) 2.45
Microbial influences on the small intestinal response to radiation injury. Curr Opin Gastroenterol (2010) 1.10
Gastrointestinal radiation injury: symptoms, risk factors and mechanisms. World J Gastroenterol (2013) 1.06
Nutritional screening and early treatment of malnutrition in cancer patients. J Cachexia Sarcopenia Muscle (2011) 1.05
The effect on the small bowel of 5-FU and oxaliplatin in combination with radiation using a microcolony survival assay. Radiat Oncol (2009) 0.84
The advantage of 3D conformal treatment of lumbar spine metastases in comparison to traditional PA or AP-PA techniques: restoring an intermediate niche of therapeutic sophistication. Radiat Oncol (2013) 0.83
Assessment of long-term rectal function in patients who received pelvic radiotherapy: a pooled North Central Cancer Treatment Group trial analysis, N09C1. Support Care Cancer (2013) 0.82
Small bowel toxicity after high dose spot scanning-based proton beam therapy for paraspinal/retroperitoneal neoplasms. Strahlenther Onkol (2013) 0.80
Practical approaches to effective management of intestinal radiation injury: benefit of resectional surgery. World J Gastroenterol (2011) 0.79
Predictors of acute gastrointestinal toxicity during pelvic chemoradiotherapy in patients with rectal cancer. Gastrointest Cancer Res (2013) 0.79
Current treatment of rectal cancer adapted to the individual patient. Rep Pract Oncol Radiother (2013) 0.79
Exploring a link between fatigue and intestinal injury during pelvic radiotherapy. Oncologist (2010) 0.78
Pelvic Ewing sarcomas. Three-dimensional conformal vs. intensity-modulated radiotherapy. Strahlenther Onkol (2013) 0.78
Acute small-bowel toxicity during neoadjuvant combined radiochemotherapy in locally advanced rectal cancer: determination of optimal dose-volume cut-off value predicting grade 2-3 diarrhoea. Radiat Oncol (2015) 0.78
Effect of different treatment plans on irradiated small-bowel volume in gynecologic patients undergoing whole-pelvic irradiation. J Radiat Res (2013) 0.77
Neoadjuvant therapy before surgical treatment. EJC Suppl (2013) 0.77
Radiotherapy for Stage IIA seminoma: The Northern Israel Oncology Center Experience, 1971-2010. Rep Pract Oncol Radiother (2014) 0.75
A randomized study of the effect of patient positioning on setup reproducibility and dose distribution to organs at risk in radiotherapy of rectal cancer patients. Radiat Oncol (2015) 0.75
Comparison of conventional and three-dimensional conformal CT planning techniques for preoperative chemoradiotherapy for locally advanced rectal cancer. Br J Radiol (2011) 0.75
Predictors of Radiation Therapy-Related Gastrointestinal Toxicity From Anal Cancer Dose-Painted Intensity Modulated Radiation Therapy: Secondary Analysis of NRG Oncology RTOG 0529. Int J Radiat Oncol Biol Phys (2017) 0.75
[Concurrent radiochemotherapy for the treatment of solid tumors]. Strahlenther Onkol (2012) 0.75
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A (2007) 5.44
The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res (2008) 4.63
Serum cystatin C reflects glomerular endotheliosis in normal, hypertensive and pre-eclamptic pregnancies. BJOG (2003) 4.10
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol (2012) 3.95
Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome. J Clin Oncol (2010) 2.49
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst (2002) 2.25
Loss of Wnt-5a protein is associated with early relapse in invasive ductal breast carcinomas. Cancer Res (2002) 1.93
Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. Breast Cancer Res (2007) 1.91
Potent amyloidogenicity and pathogenicity of Aβ43. Nat Neurosci (2011) 1.76
Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential. BMC Genomics (2007) 1.71
Does analysis of biomarkers in tumor cells in lymph node metastases give additional prognostic information in primary breast cancer? World J Surg (2010) 1.68
FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck (2002) 1.66
Patterns of chromosomal imbalances defines subgroups of breast cancer with distinct clinical features and prognosis. A study of 305 tumors by comparative genomic hybridization. Cancer Res (2003) 1.65
Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma. Clin Cancer Res (2007) 1.54
CD40 is a potential marker of favorable prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Leuk Lymphoma (2010) 1.41
[Health personnel's dress-code must combine confidence and good hygiene]. Lakartidningen (2007) 1.39
Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial. Breast Cancer Res Treat (2013) 1.38
Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification. Cancer Res (2005) 1.34
CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers. BMC Cancer (2011) 1.31
Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes. Mol Oncol (2012) 1.24
Molecular profiling reveals low- and high-grade forms of primary melanoma. Clin Cancer Res (2012) 1.17
Perforated peptic duodenal ulcer in a paraesophageal hernia--a case report of a rare surgical emergency. BMC Surg (2006) 1.17
Radiobiological risk estimates of adverse events and secondary cancer for proton and photon radiation therapy of pediatric medulloblastoma. Acta Oncol (2011) 1.15
Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer. Breast Cancer Res Treat (2007) 1.14
Prognostic impact of array-based genomic profiles in esophageal squamous cell cancer. BMC Cancer (2008) 1.12
Glomerular endotheliosis in normal pregnancy and pre-eclampsia. BJOG (2003) 1.10
Endothelial basement membrane laminin alpha5 selectively inhibits T lymphocyte extravasation into the brain. Nat Med (2009) 1.10
Characterization of a novel breast carcinoma xenograft and cell line derived from a BRCA1 germ-line mutation carrier. Lab Invest (2003) 1.10
Knowledge about hereditary nonpolyposis colorectal cancer; mutation carriers and physicians at equal levels. BMC Med Genet (2009) 1.10
Nuclear deadenylation/polyadenylation factors regulate 3' processing in response to DNA damage. EMBO J (2010) 1.08
The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer. Mod Pathol (2009) 1.07
Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer. Breast Cancer Res Treat (2009) 1.07
Nuclear Janus-activated kinase 2/nuclear factor 1-C2 suppresses tumorigenesis and epithelial-to-mesenchymal transition by repressing Forkhead box F1. Cancer Res (2010) 1.05
Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer. J Clin Oncol (2007) 1.04
Ultraviolet photodegradation of folic acid. J Photochem Photobiol B (2005) 1.03
Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up. Breast Cancer Res Treat (2013) 1.02
Comparison of immunohistochemical and biochemical assay of steroid receptors in primary breast cancer--clinical associations and reasons for discrepancies. Acta Oncol (2003) 1.02
Percutaneous cholecystostomy: a bridge to surgery or definite management of acute cholecystitis in high-risk patients? Scand J Gastroenterol (2008) 1.00
Structural basis of m(7)GpppG binding to poly(A)-specific ribonuclease. Structure (2009) 1.00
Inhibition of mRNA deadenylation by the nuclear cap binding complex (CBC). J Biol Chem (2005) 1.00
Evaluation of the tissue microarray technique for immunohistochemical analysis in rectal cancer. Arch Pathol Lab Med (2002) 0.99
In vitro radiosensitization by oxaliplatin and 5-fluorouracil in a human colon cancer cell line. Acta Oncol (2005) 0.99
Indistinguishable genomic profiles and shared prognostic markers in undifferentiated pleomorphic sarcoma and leiomyosarcoma: different sides of a single coin? Lab Invest (2009) 0.98
Cytogenetic characterization and gene expression profiling of the trastuzumab-resistant breast cancer cell line JIMT-1. Cancer Genet Cytogenet (2007) 0.98
Brain inflammation induces post-synaptic changes during early synapse formation in adult-born hippocampal neurons. Exp Neurol (2013) 0.98
Ki67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies. BMC Cancer (2011) 0.98
Regression of cervical spinal cord compression in a patient with chordoma following treatment with cetuximab and gefitinib. Acta Oncol (2009) 0.95
A systematic overview of radiation therapy effects in non-small cell lung cancer. Acta Oncol (2003) 0.95
Epidermal growth factor receptor status and persistent activation of Akt and p44/42 MAPK pathways correlate with the effect of cetuximab in head and neck and colon cancer cell lines. J Cancer Res Clin Oncol (2008) 0.95
Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: Results from a controlled randomised trial. Eur J Cancer (2009) 0.95
The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer: results from the Nordic ACT trial. Int J Colorectal Dis (2011) 0.94
A prospective study of different types of hormone replacement therapy use and the risk of subsequent breast cancer: the women's health in the Lund area (WHILA) study (Sweden). Cancer Causes Control (2003) 0.94
Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis. Cancer (2002) 0.94
Genome-wide search for breast cancer linkage in large Icelandic non-BRCA1/2 families. Breast Cancer Res (2010) 0.93
Immunohistochemical patterns in rectal cancer: application of tissue microarray with prognostic correlations. Int J Cancer (2004) 0.93
Improved prognostication in soft tissue sarcoma: independent information from vascular invasion, necrosis, growth pattern, and immunostaining using whole-tumor sections and tissue microarrays. Hum Pathol (2005) 0.92
Gene expression profilers and conventional clinical markers to predict distant recurrences for premenopausal breast cancer patients after adjuvant chemotherapy. Eur J Cancer (2006) 0.91
Life years lost--comparing potentially fatal late complications after radiotherapy for pediatric medulloblastoma on a common scale. Cancer (2012) 0.91
Weight and body mass index in relation to irradiated volume and to overall survival in patients with oropharyngeal cancer: a retrospective cohort study. Radiat Oncol (2014) 0.90
Estrogen and progesterone receptor assay in paraffin-embedded breast cancer--reproducibility of assessment. Acta Oncol (2003) 0.90
The prognostic value of mitotic activity index (MAI), phosphohistone H3 (PPH3), cyclin B1, cyclin A, and Ki67, alone and in combinations, in node-negative premenopausal breast cancer. PLoS One (2013) 0.90
Expression profiling using tissue microarray in 211 malignant fibrous histiocytomas confirms the prognostic value of Ki-67. Virchows Arch (2004) 0.89
High tumor tissue concentration of plasminogen activator inhibitor 2 (PAI-2) is an independent marker for shorter progression-free survival in patients with early stage endometrial cancer. Int J Cancer (2002) 0.88
Reproducibility of human epidermal growth factor receptor 2 analysis in primary breast cancer: a national survey performed at pathology departments in Sweden. Acta Oncol (2009) 0.88
Two-year results from a Swedish study on conventional versus accelerated radiotherapy in head and neck squamous cell carcinoma--the ARTSCAN study. Radiother Oncol (2011) 0.88
Vascular endothelial growth factor is a strong predictor of early distant recurrences in a prospective study of premenopausal women with lymph-node negative breast cancer. Breast (2008) 0.88
Cetuximab sensitivity associated with oxaliplatin resistance in colorectal cancer. Anticancer Res (2012) 0.88
Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients. Thromb Haemost (2003) 0.87
Analysis of and prognostic information from disseminated tumour cells in bone marrow in primary breast cancer: a prospective observational study. BMC Cancer (2012) 0.87
A novel model for Ki67 assessment in breast cancer. Diagn Pathol (2014) 0.86
What's new in target volume definition for radiologists in ICRU Report 71? How can the ICRU volume definitions be integrated in clinical practice? Cancer Imaging (2007) 0.86
Radiation-induced trismus in the ARTSCAN head and neck trial. Acta Oncol (2014) 0.86
Autocrine epidermal growth factor receptor ligand production and cetuximab response in head and neck squamous cell carcinoma cell lines. J Cancer Res Clin Oncol (2011) 0.86
Poly(A)-specific ribonuclease (PARN): an allosterically regulated, processive and mRNA cap-interacting deadenylase. Crit Rev Biochem Mol Biol (2013) 0.86
Early changes in 2-deoxy-2-[18F]fluoro-D-glucose metabolism in squamous-cell carcinoma during chemotherapy in vivo and in vitro. Cancer Biother Radiopharm (2009) 0.86
Training artificial neural networks directly on the concordance index for censored data using genetic algorithms. Artif Intell Med (2013) 0.86
Prediction of outcome after diagnosis of metachronous contralateral breast cancer. BMC Cancer (2011) 0.86
Mapping of a novel ocular and cutaneous malignant melanoma susceptibility locus to chromosome 9q21.32. J Natl Cancer Inst (2005) 0.86
Can tissue microarray-based analysis of protein expression predict recurrence of stage Ta bladder cancer? Scand J Urol Nephrol (2011) 0.86
Ezrin expression predicts local recurrence and development of metastases in soft tissue sarcomas. J Clin Pathol (2011) 0.86
Weight loss in patients with head and neck cancer during and after conventional and accelerated radiotherapy. Acta Oncol (2012) 0.85
Recognition of adenosine residues by the active site of poly(A)-specific ribonuclease. J Biol Chem (2009) 0.85
Low-dose hormone therapy and carbohydrate metabolism. Fertil Steril (2003) 0.85
NTCP modelling and pulmonary function tests evaluation for the prediction of radiation induced pneumonitis in non-small-cell lung cancer radiotherapy. Phys Med Biol (2007) 0.85
Altered synaptic properties during integration of adult-born hippocampal neurons following a seizure insult. PLoS One (2012) 0.85
Complement C3 and C5 deficiency affects fracture healing. PLoS One (2013) 0.84
Differences in estimates of cisplatin-induced cell kill in vitro between colorimetric and cell count/colony assays. In Vitro Cell Dev Biol Anim (2007) 0.84
Particle therapy - a next logical step in the improvement of radiotherapy. Acta Oncol (2011) 0.84